Ultragenyx Pharmaceutical Balance Sheet Health
Financial Health criteria checks 5/6
Ultragenyx Pharmaceutical has a total shareholder equity of $275.4M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $1.5B and $1.2B respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
Interest coverage ratio | n/a |
Cash | US$577.21m |
Equity | US$275.41m |
Total liabilities | US$1.22b |
Total assets | US$1.49b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: RARE *'s short term assets ($732.2M) exceed its short term liabilities ($280.4M).
Long Term Liabilities: RARE *'s short term assets ($732.2M) do not cover its long term liabilities ($935.2M).
Debt to Equity History and Analysis
Debt Level: RARE * is debt free.
Reducing Debt: RARE * has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: RARE * has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: RARE * has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of 12.8% each year.